« Return to News | CROs/Service Providers

Prestwick, Pharma Plexus form strategic alliance

Tuesday, December 13, 2011 11:44 AM

Prestwick Chemical, a chemical services company for the life sciences industry, has formed a strategic alliance with Pharma Plexus Holland, a provider of pharmaceutical optimization and development services. The two companies will work together on a significant lead optimization project recently won from a major pharmaceutical company.

With this new partnership, the two companies can offer enhanced multidisciplinary research services to life science companies worldwide. The two companies will be working together to provide lead optimization and library services, large-scale synthesis and expect to offer further drug discovery services in the future.
 
“Prestwick Chemical was looking at solutions to expand its capacity and ability to handle larger projects in the face of growing demand,” said Professor Thierry Langer, CEO of Prestwick Chemical. “The collaboration with Pharma Plexus Holland in Weesp near Amsterdam is a great opportunity to do just this. It also allows us to address the additional needs of our clients and prospects. In Weesp, we have found scientists and entrepreneurs whose culture for excellence is perfectly aligned with that of our own scientists and we are looking forward to a long and successful collaboration.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.